会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
    • 苯基和苯基烷基取代的乙醇胺和乙二胺
    • US06770636B2
    • 2004-08-03
    • US09912163
    • 2001-07-24
    • Klaus FuchsWerner StranskyMatthias GrauertAdrian CarterWolfram GaidaThomas WeiserHelmut Ensinger
    • Klaus FuchsWerner StranskyMatthias GrauertAdrian CarterWolfram GaidaThomas WeiserHelmut Ensinger
    • A61K3133
    • C07D295/125C07C211/35C07C217/48C07C2601/02C07C2601/14C07C2601/16C07D231/12C07D233/56C07D249/08C07D295/092
    • Compounds of formula 1, wherein: R1 is hydrogen, hydroxy, CF3, NO2, CN, halogen, C1-C8-alkyl, or C1-C8-alkoxy; R2, R3, and R4 independently of one another are hydrogen, C1-C8-alkyl, hydroxy, NO2, CN, C1-C8-alkoxyl, CF3, or halogen; R5 and R6 independently of one another are hydrogen or a group consisting of C1-C8-alkyl, C2-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C6-alkylene, C5-C8-cycloalkenyl, C5-C8-cycloalkenyl-C1-C6-alkylene, C6-C10-aryl, and C6-C10-aryl-C1-C6-alkylene, each optionally substituted by a group consisting of C1-C6-alkyl, C2-C6-alkenyl, halogen, C1-C6-alkyloxy, —NH2, —NH(C1-C4-alkyl), —N(C1-C4-alkyl)2, hydroxy, ═O, —COOH, —CO—OC1-C4-alkyl, —CONH2, —CONH(C1-C4-alkyl), —CON(C1-C4-alkyl)2, and CF3, or R5 and R6 together with the nitrogen atom are a saturated or unsaturated 5-, 6-, 7-, or 8-membered heterocyclic group optionally containing one or two further heteroatoms consisting of sulfur, oxygen, and nitrogen, and optionally mono-, di-, or trisubstituted by a group consisting of C1-C4-alkyl, hydroxy, ═O, —COOH, —CO—OC1-C4-alkyl, —CONH2, —CONH(C1-C4-alkyl), —CON(C1-C4-alkyl)2, halogen, and benzyl; X is oxygen, —NH—, —N(CHO)—, —N(CO—C1-C6-alkyl), —N(C1-C6-alkyl), or —N(C3-C6-cycloalkyl-C1-C4-alkylene); and A is a group consisting of C1-C6-alkylene, C2-C6-alkenylene, and C3-C6-alkynylene, each optionally substituted by a group consisting of halogen, ═O, and hydroxy, or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of making such compounds; pharmaceutical compositions thereof, and their use in treating or preventing certain diseases.
    • 式1的化合物,其中:R 1是氢,羟基,CF 3,NO 2,CN,卤素,C 1 -C 8 - 烷基或C 1 -C 8 - 烷氧基; R 2,R 3, 4>彼此独立地是氢,C 1 -C 8 - 烷基,羟基,NO 2,CN,C 1 -C 8 - 烷氧基,CF 3或卤素; R 5和R 6彼此独立地是氢或基团 由C 1 -C 8 - 烷基,C 2 -C 8 - 烯基,C 3 -C 8 - 炔基,C 3 -C 8 - 环烷基,C 3 -C 8 - 环烷基-C 1 -C 6亚烷基,C 5 -C 8 - 环烯基,C 5 -C 8 - 环烯基 - C 1 -C 6 - 亚烷基,C 6 -C 10 - 芳基和C 6 -C 10 - 芳基-C 1 -C 6亚烷基,各自任选被C 1 -C 6 - 烷基,C 2 -C 6 - 烯基,卤素,C 1 -C 6 - 烷氧基,-NH 2,-NH(C 1 -C 4 - 烷基),-N(C 1 -C 4 - 烷基)2,羟基,= O,-COOH,-CO-OC 1 -C 4烷基,-CONH 2,-CONH C 1 -C 4烷基),-CON(C 1 -C 4 - 烷基)2和CF 3或R 5和R 6与氮原子一起为饱和或不饱和的5-,6-,7-或 任选地含有一个或两个由硫,氧和氮组成的另外的杂原子的8-元杂环基,以及任选的单 - ,二 - ,或被由C 1 -C 4 - 烷基,羟基,O,-COOH,-CO-OC 1 -C 4烷基,-CONH 2,-CONH(C 1 -C 4 - 烷基),-CON(C 1 -C 4) - 烷基)2,卤素和苄基; X是氧,-NH-,-N(CHO) - , - N(CO-C 1 -C 6烷基), - N(C 1 -C 6 - 烷基) (C 3 -C 6 - 环烷基-C 1 -C 4 - 亚烷基); 并且A是由C 1 -C 6亚烷基,C 2 -C 6亚烯基和C 3 -C 6亚炔基组成的基团,各自任选地被卤素,= O和羟基取代,或光学异构体,对映体,互变异构体, 游离碱或其药理学上可接受的酸加成盐; 制备此类化合物的方法; 其药物组合物及其在治疗或预防某些疾病中的用途。
    • 6. 发明授权
    • Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
    • 取代的1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖嗪及其作为药物组合物的用途
    • US06387921B1
    • 2002-05-14
    • US09995382
    • 2001-11-27
    • Matthias GrauertAdrian CarterThomas WeiserHelmut EnsingerWolfram GaidaJoachim Mierau
    • Matthias GrauertAdrian CarterThomas WeiserHelmut EnsingerWolfram GaidaJoachim Mierau
    • A61K314748
    • C07D405/06C07D221/26
    • Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines of general formula 1: wherein: R1 and R2, which are identical or different, are each hydrogen, C1-C6-alkyl, C1--C6-alkyloxy, OH, F, Cl, or Br; R3 is hydrogen, F, Cl, Br, methyl, ethyl, OH, or methoxy; R4 and R5, which are identical or different, are each hydrogen, methyl, or ethyl; R6 is hydrogen; X is NH2, NH—(C1-C6-alkyl), N(C1-C6-alkyl)2, the two C1-C6-alkyl groups of which are identical or different, NH—COH, NH—CO(C1-C6-alkyl), or F; A is —(CH2)3—, —CH2—CH2—O—, —CH2—O—CH2—, —(CH2)4—, —CH(C1-C6-alkyl)-O—CH2—, —(CH2)2—O—CH2—, —(CH2)3—O—, —(CH2)5—, —CH2—O—(CH2)3—, —(CH2)2—O—(CH2)2—, —(CH2)3—O—CH2—, —(CH2)4—O—, —CH2—O—CH2—CH2—O—, the racemates thereof, the enantiomers thereof, the diastereomers thereof, and mixtures thereof, and the pharmacologically acceptable acid addition salts thereof, processes for preparing them, and their use as pharmaceutical compositions.
    • 取代的通式1的1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖嗪:其中:R 1和R 2各自相同或不同,为氢,C 1 -C 6 - 烷基 ,C 1 -C 6烷氧基,OH,F,Cl或Br; R 3是氢,F,Cl,Br,甲基,乙基,OH或甲氧基; R 4和R 5各自相同或不同, 甲基或乙基; R6是氢; X是NH2,NH-(C1-C6-烷基),N(C1-C6-烷基)2,它们的两个C1-C6-烷基相同或不同,NH- COH,NH-CO(C1-C6-烷基)或F; A是 - (CH2)3-,-CH2-CH2-O-,-CH2-O-CH2-, - (CH2) (C 1 -C 6 - 烷基)-O-CH 2 - , - (CH 2)2 -O-CH 2 - , - (CH 2)3 -O - , - (CH 2) , - (CH 2)2 -O-(CH 2)2 - , - (CH 2)3 -O-CH 2 - , - (CH 2)4 -O - , - CH 2 -O-CH 2 -CH 2 -O-, ,其对映异构体,其非对映体及其混合物,及其药学上可接受的酸加成盐,其制备方法及其作为药物组合物的用途。
    • 7. 发明授权
    • Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
    • 取代的1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖嗪及其作为药物组合物的用途
    • US06355652B1
    • 2002-03-12
    • US09699748
    • 2000-10-30
    • Matthias GrauertAdrian CarterThomas WeiserHelmut EnsingerWolfram GaidaJoachim Mierau
    • Matthias GrauertAdrian CarterThomas WeiserHelmut EnsingerWolfram GaidaJoachim Mierau
    • A61K31439
    • C07D405/06C07D221/26
    • Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines of general formula 1: wherein: R1 and R2, which may be identical or different, are each hydrogen, C1-C6-alkyl, C1-C6-alkyloxy, OH, F, Cl, or Br; R3 is hydrogen, F, Cl, Br, methyl, ethyl, OH, or methoxy; R4, R5, and R6, which may be identical or different, are each hydrogen, methyl, or ethyl; X is NH2, NH-(C1-C6-alkyl), N(C1-C6-alkyl)2, the two C1-C6-alkyl groups of which may be identical or different, NH—COH, NH—CO(C1-C6-alkyl), or F; A is —(CH2)3—, —CH2—CH2—O—, —CH2—O—CH2—, —(CH2)4—, —CH(C1-C6-alkyl)-O—CH2—, —(CH2)2—O—CH213 , —(CH2)3—O—, —(CH2)5—, —CH2—O—(CH2)3—, —(CH2)2—O—(CH2)2—, —(CH2)3—O—CH2—, —(CH2)4—O—, —CH2—O—CH2—CH2—O—,  the racemates thereof, the enantiomers thereof, the diastereomers thereof, and mixtures thereof, and the pharmacologically acceptable acid addition salts thereof, processes for preparing them, and their use as pharmaceutical compositions.
    • 取代的通式1的1,2,3,4,5,6-六氢-2,6-亚甲基-3-苯并吖嗪:其中:R 1和R 2可以相同或不同,各自为氢,C 1 -C 6 - 烷基,C 1 -C 6烷氧基,OH,F,Cl或Br; R 3是氢,F,Cl,Br,甲基,乙基,OH或甲氧基; R 4,R 5和R 6可以相同或不同, 各自为氢,甲基或乙基; X为NH 2,NH-(C 1 -C 6 - 烷基),N(C 1 -C 6烷基)2,其两个C 1 -C 6 - 烷基可以相同或不同,NH -COH,NH-CO(C 1 -C 6烷基)或F; A是 - (CH 2)3 - , - CH 2 -CH 2 -O - , - CH 2 -O-CH 2 - , - (CH 2) CH(C 1 -C 6 - 烷基)-O-CH 2 - , - (CH 2)2 -O-CH 2 13, - (CH 2)3 -O-, - (CH 2) , - (CH 2)2 -O-(CH 2)2 - , - (CH 2)3 -O-CH 2 - , - (CH 2)4 -O - , - CH 2 -O-CH 2 -CH 2 -O-, ,其对映异构体,其非对映体及其混合物,及其药学上可接受的酸加成盐,其制备方法及其作为药物组合物的用途。